Ganoderic Acid A alleviates ulcerative colitis by inhibiting the interleukin17 signaling pathway via targeting retinoic acid-related orphan receptor alpha

Key Points

• Ganoderic Acid A significantly reduces inflammation in ulcerative colitis, indicating its therapeutic value.
• Key measure shows decreased IL-17 pathway activation following treatment with Ganoderic Acid A.
• The approach involves assessing how Ganoderic Acid A interacts with the RORA receptor to target inflammatory responses.
• This study suggests that Ganoderic Acid A could be an effective nutritional intervention, requiring further investigations.